<DOC>
	<DOCNO>NCT02002611</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetic drug interaction lobeglitazone warfarin healthy subject .</brief_summary>
	<brief_title>Drug-drug Interaction Study ( Lobeglitazone , Warfarin )</brief_title>
	<detailed_description>From day 1 day 12 , lobeglitazone 0.5mg administered daily Group 1 subject period 1 . Then day 5 , warfarin 25mg co-administered Group 1 subject period 1 . After 10 day-break , warfarin 25mg administer Group 1 subject period 2 . On period 2 , lobeglitazone administer . Group 2 administer reverse order .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>A healthy male volunteer 19 55 year old . BMI 19 27 . Signed informed consent form prior study participation . Able participate entire trial Clinically significant hepatic , renal , digestive system , respiratory system , endocrine system , nervous system , hematologic , cardiovascular system , tumor history tumor Clinically significant hemorrhagic disease Genetic problem galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption Have hypersensitivity reaction history lobeglitazone , warfarin , excipient IP aspirin , antibiotic Medication might significantly alter absorption , distribution , metabolism , excretion investigational product within 30 day prior screen Participated clinical trial administrate IP within 60 day prior screen Subject take ethical drug herbal medicine within 14 day , OTC within 7 day screen Previously donate whole blood within 60 day component blood within 30 day sit SBP &lt; 90mmHg sit SBP ≥ 140mmHg sit DBP &lt; 60mmHg sit DBP ≥ 90mmHg A heavy alcohol consumer ( alcohol &gt; 140 g/week ) stop drink A heavy smoker ( cigarette &gt; 10 cigarette per day ) stop smoke A heavy caffeine consumer ( 4cups per day ) A heavy grapefruit consumer ( 1cup per day ) stop Positive Triage TOX drug urine Positive HIV antibody , HBsAg , HCV antibody test AST , ALT Total bilirubin &gt; UNL * 1.5 Estimated GFR &lt; normal limit INR , aPTT normal limit Clinically significant laboratory test result Clinically significant ECG An impossible one participate clinical trial investigator 's decision include reason</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Lobeglitazone</keyword>
	<keyword>Warfarin</keyword>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Drug-Drug interaction</keyword>
	<keyword>Phase 1</keyword>
</DOC>